Articles On Rhythm Biosciences (ASX:RHY)

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

The ASX 200 closed lower today, falling 0.49 per cent to close at 7199.2 points. It came after the Australian Bureau of Statistics revealed wage prices are still too high. In the green Information technology was the standout sector...

Rhythm Biosciences’ (RHY) share price more than doubles after securing regulatory approval for its colon cancer detection blood test in the UK The UKCA mark certification has been granted for ColoSTAT – an affordable and user-friendly bl...

The Wage Price Index (WPI) has lifted to its highest level in more than ten years. That’s according to the latest data from the Australian Bureau of Statistics (ABS). The index increased point-eight per cent in the March quarter of 2023,...

17 May 2023 - A snapshot of the stocks on the move featuring Magnis Energy Technologies (ASX:MNS), QX Resources (ASX:QXR), Rhythm Biosciences (ASX:RHY) and Wildcat Resources (ASX:W…

The All Ordinaries Index (ASX: XAO) is down 0.42% in lunchtime trading, but this ASX All Ords biotech stock is bucking the trend. The Rhythm Biosciences Ltd (ASX: RHY) share price is rocketing 120% higher today to 77 cents. Let’s take a...

ShareCafeASX down 0.51% at noon as Australian wages grow by Peter Milios   At noon, the S&P/ASX 200 is 0.51 per cent lower at 7,198.10, after initially dropping as much as 1 per cent at the opening. Meanwhile, in Wall Street trading, th...

ShareCafeStocks of the Hour: MNS, QXR, RHY, WC8                    Magnis Energy Technologies (ASX:MNS; OTCQX: MNSEF; FSE:U1P) has announced that their lithium ion cell manufacturer iM3NY has entered into a JV Agreement with OSM. iM3N...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] A simple blood test used for the detection of colorectal cancer has achieved UK Conformity Assessed (UKCA) marking for developer Rhythm Biosciences (ASX: RHY). The reg...

Rhythm Biosciences surged 70pc this morning after being granted the UK CA Mark for ColoSTAT Anteris Tech was issued another patent in the US Immutep reported positive Phase 2 results   It’s a big day for medical diagnostics company Rhythm...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Control Bionics launched the world’s first autonomous driving wheelchair, DROVE Anteris Technologies to develop an innovative heart valve repair device. Rhythym Bio CEO resigns   Control Bionics (ASX:CBL) will today launch the world’s fir...

Noxopharm plunged 45pc after scaling down its Veyonda program Rhythm Biosciences rose 25pc after saying that ColoSTAT will be presented at a prestigious gathering Immuron surged 24% as global sales rose significantly   Noxopharm (ASX:NOX)...

The Rhythm Biosciences Ltd (ASX: RHY) share price had a day to forget on Monday. The medical diagnostics technology’s shares returned from a trading halt and crashed as much as 52% to 46 cents. The ASX All Ords share ultimately recovered...

RooLife is today’s ASX winner after getting its drinks into China’s massive Freshippo market The Benchmark climbed early but sagged like a horrid old balloon to end the day around +0.5% Harris tells Credit Suisse “it’s not us, it’s you” an...

Cancer diagnostics technology company Rhythm Biosciences (RHY) withdraws its TGA application for its ColoSTAT technology The withdrawal comes after the company received feedback from the TGA and concluded it wouldn’t be able to answer al...

Rhythm plunged 45% this morning after announcing some TGA news The FDA has cleared PYC Therapeutics for first ever human trial on Retinitis Pigmentosa Type 11   Rhythm Biosciences (ASX: RHY) crashed 47% this morning after withdrawing its...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The ASX got an Data Nerd Bailout when the ABS dropped happy-ish CPI data The benchmark recovers from early flesh wounds to end the day flat Ordinary Aussies ‘outraged’ over changes to super that will never, ever affect them The market has...

Zelira Therapeutics (ZLD) promotes Greg Blake to the role of Executive Director Mr Blake joined the company in 2020 and has been serving as Vice President, Global Head of Commercial and Partnering After more than 20 years working in t...

Rhythm Biosciences (RHY) retains its ISO certification for a fifth consecutive year The certification means Rhythm has met the international standard for in-vitro diagnostics and medical devices for its ColoSTAT blood test product Rh...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Rhythm Biosciences (RHY) appoints a second bioanalytical partner to advance its development program into additional cancer areas    The company has been working to develop simple, affordable and highly accurate blood tests for the detection...

Rhythm partners with the Baker Institute to expand cancer program Island Pharma gets ethics approval in the US   Rhythm Biosciences (ASX:RHY) will advance a development program into additional cancers after appointing the Baker Institute...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Australian health stocks sightly up for the week with optimistism of a traditional end-of-year rally In positive news several healthcare names deliver strong quarterly results and forecasts Morgans upgrades Nanonosonics from Hold to Add an...

ShareCafeA sea of red in today’s trading: ASX closes 1.84% lower by Peter Milios   All but one sector finished lower today, as the ASX reacted to the overnight news that the Fed has increased rates by 75 basis points. Materials, Consumer Di...

The All Ordinaries Index (ASX: XAO) is 1.85% in the red today, but these four All Ords shares are soaring higher. The A2 Milk Company Ltd (ASX: A2M), Perpetual Ltd (ASX: PPT), RHYTHM Biosciences Ltd (ASX: RHY) and Weebit Nano Ltd (ASX:...

ShareCafeAll red across the board following US rate hike sentiment: ASX down 1.96% at noon By Lauren Hayes   US equities plunged after Fed Chair Jerome Powell indicated policymakers would continue raising interest rates to fight persistent...

ShareCafeStocks of the Hour: RHY, A2M, NFL                    Rhythm Biosciences Ltd (ASX:RHY) confirmed this morning the expansion of its international regulatory footprint, having successfully registered ColoSTAT® with the New Zeala...

The All Ordinaries Index (ASX: XAO) may be sinking today but that hasn’t stopped a couple of ASX healthcare shares from racing higher. Here’s why these two All Ords shares are smashing the index on Thursday: Immutep Ltd (ASX: IMM) The...

HitIQ signs deal with Western Australian Football Commission Rhthym Bio expands into NZ Immutep’s Phase II TACTI-002 trial has been accepted for an oral presentation HitIQ signs with WAFC Concussion tech specialist HitIQ (ASX:HIQ) rose 40...

03 Nov 2022 - A snapshot of the stocks on the move featuring Rhythm Biosciences (ASX:RHY), The a2 Milk Company (ASX:A2M) and Norfolk Metals (ASX:NFL).

Rhythm Biosciences (RHY) successfully registers its ColoSTAT cancer detection product with the New Zealand national database of Medical DevicesThe registration allows the technology to be marketed and sold in the countryColoSTAT is a low-co...

Cancer diagnostics technology company, Rhythm Biosciences (ASX:RHY), has secured authorisation for ColoSTAT in New Zealand.

Highlights The ASX 200 benchmark index closed down today (21 October), losing 53.90 points or 0.80% to end at 6,676.80 points. Over the last five days, the index has lost 1.21% and 9.96% over the last 52 weeks. Utilities and materials...

Rhythm Biosciences (RHY) receives a $2.7 million research and development tax refundThe funds comes as part of the Australian government’s research and development tax incentive, which recognises R&D undertaken during the financial year...

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

Billionaire investor Alex Waislitz tops up holding in Thorney Technologies which now has a stake in Splitit Data Analytics company Nuix sees its CEO bullish on the company, which is the target of takeover speculation Carsales.com has seen...

The Rhythm Biosciences Ltd (ASX: RHY) share price is in the green during morning trade on Friday. This comes after the ASX All Ords company announced that its executive chair has just offloaded $6.5 million worth of his shares. At the ti...

As with your columnist, plenty of other Australians aged between 50 and 74 are suffering from “poo-crastination”. Every two years, anyone in that cohort receives a bowel cancer test kit from the Federal Health Department, which requires the...

MoneyTalks is Stockhead’s regular drill down into what stocks investors are looking at right now. We’ll tap our extensive list of experts to hear what’s hot, their top picks, and what they’re looking out for. Today we hear from Pac Partners...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

Rhythm Biosciences (RHY) completes its initial biomarker review to support platform expansion of its core detection technology, ColoSTAT With the first phase of the expansion complete, the company will turn its focus on accelerating the ne...

Highlights Rhythm Biosciences has identified leading biomarkers that are critical for progressing research and development of several target cancers The key lead biomarker for ColoSTAT®, Rhythm’s initial bowel cancer product, offers a...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

ASX Health stocks endure another topsy-turvy week ending in red Monash IVF makes two key purchases to expand its foothold in fertility sector Actinogen Medical to push ahead with trial into treatment of early Alzheimer’s disease. Healthca...

Rhythm Biosciences (RHY) files ColoSTAT with the Australian TGA for listing on the Australian Register of Therapeutic Goods (ARTG) TGA approval is needed for Rhythm and its partners to market and sell ColoSTAT in the Australian market Rhyt...